Search icone
Search and publish your papers
Our Guarantee
We guarantee quality.
Find out more!

A Financial Comparison between Biogen and Corixa

Or download with : a doc exchange

About the author

 
Level
General public
Study
finance
School/University
northeaster...

About the document

Published date
Language
documents in English
Format
Word
Type
market study
Pages
2 pages
Level
General public
Accessed
6 times
Validated by
Committee Oboolo.com
0 Comment
Rate this document
  1. Introduction
  2. Biogen: Meeting current obligations
  3. A proxy statement
  4. The board of directors
  5. Conclusion

Based on the ratios in Appendix A, it seems that Biogen does not have a high profitability. The values of the ROE, ROA, and Earnings per Share ratios are all negative, and the Profit Margin ratio is only 1.2884%; however, when compared to its competitor, Corixa Corporation, these numbers dominate. It is a trend of the industry to produce low ratios. Biogen has a wider variety of products than its competitor, Corixa. Most of the medications that they have are being tested and are not yet for sale, as with Corixa, but Biogen clearly has a wider variety of products on the market. This is quite an advantage considering that it takes a long time for new drugs to enter the market. The cash flows from operating activities amounts to $267,077 while the net income was only $199,148. The difference between these two numbers is $67,929. This indicates that Biogen is gaining a substantial amount of money from other operating activities besides those that lead to an increase in net income. This indicates that they operate efficiently.

[...] Mullen, the Chairman, President, and CEO of the company, received a salary of $810,000 with a bonus of $800,000 over the 2002 fiscal year, making his total compensation $1,610,000. The previous year, his total compensation (salary plus bonus) amounted to $1,757,998- this indicates a decrease of from the previous year. This company seems like a safe investment opportunity. First of all, in the field of medicine, there are constantly breakthroughs and new discoveries that revolutionize the field. This company will continue to profit from such discoveries. [...]


[...] A Financial Comparison between Biogen and Corixa Based on the ratios in Appendix it seems that Biogen does not have a high profitability. The values of the ROE, ROA, and Earnings per Share ratios are all negative, and the Profit Margin ratio is only 1.2884 however, when compared to its competitor, Corixa Corporation, these numbers dominate. It is a trend of the industry to produce low ratios. Biogen has a wider variety of products than its competitor, Corixa. Most of the medications that they have are being tested and are not yet for sale, as with Corixa, but Biogen clearly has a wider variety of products on the market. [...]

Top sold for finance

The case of H&M and Inditex

 Economics & finance   |  Finance   |  Case study   |  09/29/2010   |   .pdf   |   5 pages

Limitations of using Beta as a standard measure to assess risks

 Economics & finance   |  Finance   |  Presentation   |  09/29/2010   |   .doc   |   2 pages

Recent documents in finance category

International finance distribution of currency of AUD and USD

 Economics & finance   |  Finance   |  Worksheets   |  08/05/2017   |   .doc   |   4 pages

The O.M. Scott & Sons Company - Financial analysis

 Economics & finance   |  Finance   |  Case study   |  11/22/2016   |   .doc   |   12 pages